Activity of Platinum-Based Chemotherapy in Patients With Advanced Prostate Cancer With and Without DNA Repair Gene Aberrations

IMPORTANCE: DNA repair gene aberrations occur in 20% to 30% of patients with castration-resistant prostate cancer (CRPC), and some of these aberrations have been associated with sensitivity to poly(ADP-ribose) polymerase (PARP) inhibition platinum-based treatments. However, previous trials assessing...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:JAMA Netw Open
Asıl Yazarlar: Schmid, Sabine, Omlin, Aurelius, Higano, Celestia, Sweeney, Christopher, Martinez Chanza, Nieves, Mehra, Niven, Kuppen, Malou C. P., Beltran, Himisha, Condeduca, Vincenza, Vargas Pivato de Almeida, Daniel, Cotait Maluf, Fernando, Oh, William K., Tsao, Che-Kai, Sartor, Oliver, Ledet, Elisa, Di Lorenzo, Giuseppe, Yip, Steven M., Chi, Kim N., Bianchini, Diletta, De Giorgi, Ugo, Hansen, Aaron R., Beer, Tomasz M., Pernelle, Lavaud, Morales-Barrera, Rafael, Tucci, Marcello, Castro, Elena, Karalis, Kostas, Bergman, Andries M., Le, Mo Linh, Zürrer-Härdi, Ursina, Pezaro, Carmel, Suzuki, Hiroyoshi, Zivi, Andrea, Klingbiel, Dirk, Schär, Sämi, Gillessen, Silke
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: American Medical Association 2020
Konular:
Original Investigation
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC7593810/
https://ncbi.nlm.nih.gov/pubmed/33112397
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamanetworkopen.2020.21692
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller